KELIX bio, fully owned by Mubadala Investment Company (Mubadala), has completed the acquisition of DiabTec LLC, a subsidiary of Julphar.
The acquisition strengthens Mubadala’s biologicals portfolio, supports its biomanufacturing role in the MENA region, and advances the UAE’s life sciences sector through local production. DiabTec’s facility includes 20,000-litre drug substance reactors and a cartridge fill-finish unit for drug products. Built to EU and US FDA standards, it is the only facility of its kind in the GCC.
Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform, stated that the move aligns with the group’s commitment to addressing global healthcare challenges, such as rising demand for insulin analogues. He added that it further reinforces Mubadala’s role in biomanufacturing and the UAE’s life sciences sector.
Sheikh Saqer Bin Humaid Al Qasimi, Chairman of Julphar, noted that the sale aligns with Julphar’s strategy to divest non-core assets. Hocine Sidi Said, CEO of KELIX bio, highlighted the global challenge of access to insulin analogues amidst rising diabetes cases and emphasised the company’s mission to ensure access to critical treatments.
This acquisition strengthens Mubadala’s presence in the life sciences ecosystem and complements KELIX bio’s recent purchase of four GlobalOne Healthcare Holding assets.